The global hemodialysis market size was valued at USD 89.85 billion in 2022. It is projected to reach USD 136.84 billion by 2031, growing at a CAGR of 4.8% during the forecast period (2023-2031).
Hemodialysis is a treatment therapy to filter water and wastes from the blood. Dialysis is the removal of waste products such as creatinine and urea and free water from the blood during kidney failure. According to the National Chronic Kidney Disease Fact Sheet, 2017, approximately 15% of the U.S. adult population was estimated to suffer from chronic kidney diseases. Diabetes and heart disease are the prime causes of kidney diseases. Thus, the increasing prevalence of diabetes and high blood pressure is expected to contribute to the growing popularity of hemodialysis. According to the National Kidney Foundation, around 10% of the global population is affected by chronic kidney disease (CKD), and millions die every year due to a lack of access to affordable treatment.
Diabetes is a chronic disease that happens when enough insulin is not produced or the body is unable to utilize the insulin it does produce. Insulin is a hormone that controls blood sugar levels. Hyperglycaemia, also known as high blood glucose or high blood sugar, is a common complication of uncontrolled diabetes and, over time, causes severe damage to numerous body systems, particularly the nerves and blood vessels. In 2014, 8.5% of 18-year-olds and older adults suffered from diabetes. In 2019, diabetes was the direct cause of 1.5 million deaths, with 48 percent of all diabetes-related deaths occurring before age 70. Diabetes caused another 460,000 kidney disease-related deaths. Diabetes affects 37.3 million Americans or roughly one in ten. 96 million adult Americans, or more than one-third, have prediabetes. The rising prevalence of kidney failure will increase the market.
In recent years, the prevalence of end-stage renal disease (ESRD) among the elderly has increased significantly more among younger individuals. Currently, the prevalence per million of ESRD is highest among those aged 65–74 years, while the incidence rate is highest among those aged 75 years and older. Given the growing number of elderly patients with end-stage renal disease (ESRD), greater consideration must be given to the treatment of this condition in this population. Hemodialysis may be performed at a center or at home for ESRD patients. The blood of the patient is passed through a filter that functions as an artificial kidney. The blood is filtered to remove excess fluid, chemicals, and waste. The blood is then reintroduced into the patient's body.
The adverse effects of the hemodialysis procedure may hinder the expansion of the global hemodialysis market. According to the National Health Service of the United Kingdom, hemodialysis is related to some side effects because it can partially compensate for impaired kidney function. Hypotension, the risk of bone and joint pain, anxiety, insomnia, and in some cases, erectile dysfunction can be side effects of hemodialysis. Consequently, such side effects may result in decreased hemodialysis treatment adoption, thereby impeding the growth of the global market.
The key players' adoption of strategies such as collaborations, mergers, and new innovations is anticipated to drive the global market. In October of 2018, Baxter Healthcare Corporation, a medical device manufacturer, collaborated with the non-profit Mayo Clinic to establish a renal care center in Florida, United States. The establishment of the center is for the benefit of patients with kidney failure and the testing of new products, such as hemodialysis machines. This could lead to greater adoption of hemodialysis machines by healthcare institutions, thereby driving the global hemodialysis market growth. In addition, in October 2016, Baxter Healthcare Corporation introduced HDx with Theranova (dialyzer), a hemodialysis machine used to treat end-stage renal disease. According to Baxter Healthcare Corporation, the dialysis machine is highly effective and functionally similar to the body's natural kidneys. It can effectively filter medium-sized molecules as well as smaller molecules. Consequently, this factor is anticipated to stimulate the expansion of the global market.
| Study Period | 2019-2031 | CAGR | 4.8% |
| Historical Period | 2019-2021 | Forecast Period | 2023-2031 |
| Base Year | 2022 | Base Year Market Size | USD 89.85 Billion |
| Forecast Year | 2031 | Forecast Year Market Size | USD 136.84 Billion |
| Largest Market | North America | Fastest Growing Market | Europe |
The global hemodialysis market is bifurcated into four regions, namely North America, Europe, Asia-Pacific, and LAMEA.
North America is the most significant holder in the global Hemodialysis market share and is anticipated to grow at a CAGR of 4.5% during the forecast period. The larger share is linked to the increasing prevalence of diabetes and advanced kidney disorders in the region. According to the National Kidney Foundation, more than 661,000 Americans have experienced kidney failure, of which 468,000 individuals are on dialysis, and roughly 193,000 live with a functioning kidney transplant. The number of American adults with chronic kidney disease (CKD) is now projected to be 37 million in 2019, according to data from the Centers for Disease Control and Prevention. This represents one in seven or 15 percent of the adult population.
Europe is expected to be the second-largest region in the market. The prevalence of diabetes and heart disease is a key cause contributing to the increasing incidences of kidney failure. According to the British Heart Foundation, during 2014–2016, over 66,000 died due to coronary heart disease in the U.K. In Europe, 100 million individuals have chronic kidney disease (CKD), and by 2040, it is expected to become the 5th most common cause of death. CKD is also one of the most costly diseases for healthcare systems, with an estimated annual cost of EUR 140 billion in Europe. Furthermore, changing eating habits and unhealthy lifestyles are expected to further fuel market growth in years to come.
Asia Pacific is expected to be the fastest-growing region in the market. In developing countries such as India, China, and Japan, treatment with dialysis or kidney transplants creates a huge financial burden. Government financial support for kidney transplants is expected to further provide impetus to market growth. Rashtriya Swasthya Bima Yojana (RSBY), which is funded by the Government of India, provides free hemodialysis to BPL (below the poverty line) families registered with RSBY.
The LAMEA region is projected to achieve stable growth in this market. Hemodialysis treatment is expensive and increasing per capita income and growing awareness regarding kidney diseases are expected to drive market growth in the region.
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
The global market is segmented by type, product, and end user.
Based on type, the global market is bifurcated into conventional, daily, and nocturnal.
The conventional segment is the highest contributor to the hemodialysis market and is expected to grow at a CAGR of 4.6% during the forecast period owing to technological advancements in safe and easy-to-use home dialysis machines. Conventional Hemodialysis is performed in a dialysis clinic three times per week for approximately four hours using any hemodialysis machine.
The daily segment is anticipated to witness significant growth. Daily hemodialysis reduces the risk of cardiovascular complications and tiredness in patients, which also increases the tolerance of sessions among patients. The overall health of advanced kidney disease patients is boosted while reducing the risk of heart disease conditions.
Based on product, the global market is bifurcated into equipment, services, consumables, and drugs.
The service segment is the highest contributor to the market and is expected to grow at a CAGR of 4.3% during the forecast period. This is due to the increasing number of dialysis service providers and the prevalence of end-stage renal disease (ESRD). In addition, a number of leading dialysis service providers plan to broaden their services by opening and acquiring new dialysis centers around the world, which is anticipated to stimulate segment growth.
The consumable segment is expected to witness significant growth during the forecast period. Increasing demand for peritoneal dialysis, which involves the use of consumables such as catheters and blood tube sets in the blood purification process and helps in balancing electrolyte levels in the blood, is expected to further drive market growth during the forecast period.
Based on end-users, the global market is bifurcated into hospital-based dialysis and home dialysis.
The hospital-based segment is the highest contributor to the market and is expected to grow at a CAGR of 4.1% during the forecast period. Due to the widespread availability of highly qualified and experienced healthcare professionals in hospitals, the segment is likely to retain its lead in the coming years. In healthcare institutions such as dialysis centers and hospitals, the presence of a qualified and knowledgeable renal care team ensures optimal treatment and improved dialysis outcomes. In addition, the increasing focus of market participants on constructing self-reliant dialysis centers and the increased adoption of patients for in-center dialysis treatment are expected to drive the segment. In addition, companies are focusing on making hemodialysis machines with a variety of treatments that are tailored to the patient. This is likely to affect the experience of the end user.
The home dialysis segment is expected to witness a higher CAGR due to convenience, time-saving, and increasing prevalence of ESRD among the geriatric population. The Advancing American Kidney Health Initiative of 2019 proposed increasing the number of U.S. patients with kidney failure who are treated at home via home hemodialysis.
